This is not a mispriced compounder; it is a speculative, cash-burning industrial science project wearing a public listing. With no P/E, no forward P/E, negative EPS of -24.7, and an operating margin of -112.30%, profitability is nowhere in sight, and the market’s 500+ Price/Sales and 27.9 Price/Book ratios reflect pure optionality rather than fundamentals. The Altman Z-Score of 56 suggests no immediate bankruptcy risk, and the 21.5 current ratio reinforces short-term liquidity strength, but that safety is balance-sheet-based, not earnings-based. At a $348M market cap with ROIC at -111.30%, this is a high-burn story stock priced on distant potential, not financial performance.